Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 775 of 1863 entries
View as:

First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody

Phase: N/A Priority: Normal
NCT ID: NCT03665155 Org: User:
Start: 09/05/18 End: 04/20/20 Due: 04/20/21

Cancer Control Following Polypectomy

Phase: N/A Priority: Normal
NCT ID: NCT00591279 Org: User:
Start: 02/28/81 End: 01/31/17 Due: 01/31/18

Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.

Phase: N/A Priority: Normal
NCT ID: NCT00590031 Org: User:
Start: 11/30/02 End: 12/31/09 Due: 12/31/10

Quantitative Dynamic Contrast Enhanced Breast MRI

Phase: N/A Priority: Normal
NCT ID: NCT00582764 Org: User:
Start: 09/30/05 End: 07/31/15 Due: 07/31/16

Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00025194 Org: User:
Start: 07/31/01 End: 07/31/06 Due: 07/31/07

Internet-based System for Cancer Patients to Self-report Toxicity

Phase: N/A Priority: Normal
NCT ID: NCT00578006 Org: User:
Start: 03/31/04 End: 01/31/17 Due: 01/31/18

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

Phase: N/A Priority: Normal
NCT ID: NCT01024946 Org: User:
Start: 12/31/09 End: 07/31/12 Due: 07/31/13

Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

Phase: N/A Priority: Normal
NCT ID: NCT01579994 Org: User:
Start: 04/16/12 End: 12/28/20 Due: 12/28/21

Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study

Phase: N/A Priority: Normal
NCT ID: NCT00597532 Org: User:
Start: 08/31/02 End: 04/30/16 Due: 04/30/17

SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study

Phase: N/A Priority: Normal
NCT ID: NCT00590564 Org: User:
Start: 10/31/02 End: 02/28/11 Due: 02/28/12

Genetic Studies in Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00582322 Org: User:
Start: 02/29/92 End: 07/31/09 Due: 07/31/10

RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01252251 Org: User:
Start: 11/30/10 End: 06/30/16 Due: 06/30/17

Comparison of Contrast Enhanced Mammography to Breast MRI in Screening Patients at Increased Risk for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01716247 Org: User:
Start: 10/31/12 End: 06/30/18 Due: 06/30/19

ILX23-7553 in Treating Patients With Solid Tumors That Have Not Responded to Previous Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00004926 Org: User:
Start: 10/31/99 End: 12/31/09 Due: 12/31/10

Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00002684 Org: User:
Start: 05/31/95 End: 10/31/07 Due: 10/31/08

Lymphedema Surveillance Study

Phase: N/A Priority: Normal
NCT ID: NCT02743858 Org: User:
Start: 04/30/16 End: 04/30/25 Due: 04/30/26

Clinical and Translational Study of STA-9090

Phase: N/A Priority: Normal
NCT ID: NCT01111838 Org: User:
Start: 04/30/10 End: 07/31/12 Due: 07/31/13

Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00550628 Org: User:
Start: 09/30/07 End: 09/30/11 Due: 09/30/12

Assessing Insulin Sensitivity and Diabetes Risk in Childhood Cancer Survivors Treated With Abdominal Irradiation

Phase: N/A Priority: Normal
NCT ID: NCT02248779 Org: User:
Start: 09/22/14 End: 10/09/19 Due: 10/09/20

Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast

Phase: N/A Priority: Normal
NCT ID: NCT00671411 Org: User:
Start: 03/31/08 End: 11/30/11 Due: 11/30/12

RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00935961 Org: User:
Start: 07/31/09 End: 08/31/13 Due: 08/31/14

Trial of IRE in Cholangiocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03769753 Org: User:
Start: 12/05/18 End: 08/16/21 Due: 08/16/22

Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion

Phase: N/A Priority: Normal
NCT ID: NCT02376127 Org: User:
Start: 02/24/15 End: 09/30/25 Due: 09/30/26

Improving Health of Patients With Colon Cancer Following Surgery: A Trial of SA-ICAN Via Videoconferencing

Phase: N/A Priority: Normal
NCT ID: NCT02301338 Org: User:
Start: 11/30/14 End: 03/16/16 Due: 03/16/17

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Phase: N/A Priority: Normal
NCT ID: NCT03215095 Org: User:
Start: 07/10/17 End: 07/31/25 Due: 07/31/26